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ABSTRACT
Objective This analysis evaluated efficacy and safety of 
filgotinib, a Janus- associated kinase 1- preferential inhibitor, 
in methotrexate (MTX)- naive patients with rheumatoid 
arthritis (RA) with multiple poor prognostic factors (PPFs).
Methods This was a post hoc analysis of the phase III, 
randomised, double- blind, active- controlled, FINCH 3 study 
( clinicaltrials. gov NCT02886728). Patients received once- 
daily oral filgotinib 200 or 100 mg plus once- weekly oral 
MTX ≤20 mg (FIL200  + MTX and FIL100  + MTX), filgotinib 
200 mg monotherapy (FIL200), or oral MTX monotherapy 
(MTX- mono) for up to 52 weeks. PPFs investigated were 
seropositivity for rheumatoid factor or anticyclic citrullinated 
peptide antibodies, high- sensitivity C reactive protein 
(CRP) ≥4 mg/L, Disease Activity Score in 28 joints with CRP 
(DAS28(CRP)) >5.1, and presence of erosions. Filgotinib 
efficacy and safety in patients with all four PPFs at baseline 
were explored versus MTX- mono within this subgroup and 
compared informally with the overall population.
Results Of 1249 patients in FINCH 3, 510 (40.8%) had all 
PPFs. Efficacy of FIL200 + MTX among these patients was 
comparable to the overall population, with higher rates of 
20%/50%/70% improvement from baseline by American 
College of Rheumatology criteria, DAS28(CRP) <2.6, and 
remission; greater improvement in physical function and 
pain; and better inhibition of structural damage relative to 
MTX- mono. FIL100 + MTX and FIL200 were not consistently 
more efficacious versus MTX- mono. Safety of filgotinib in 
patients with PPFs was comparable to the overall population; 
no new safety signals were observed.
Conclusion FIL200  + MTX efficacy and safety in patients 
with multiple PPFs were similar to the overall population.
INTRODUCTION
The 2019 EULAR guidelines for the treat-
ment of rheumatoid arthritis (RA) recom-
mend methotrexate (MTX) in combina-
tion with short- term glucocorticoids, unless 
contraindicated, as the first treatment strategy 
on diagnosis of RA.1 According to the treat- to- 
target strategy, treatment should be adjusted 
for patients who do not achieve 50% improve-
ment after approximately 3 months, as they are 
unlikely to achieve desired treatment targets 
Key messages
What is already known about this subject?
 ► Seropositivity for rheumatoid factor and anticyclic ci-
trullinated peptide antibodies, elevated acute- phase 
reactant levels, persistent moderate- to- high disease 
activity, and presence of early erosions are associat-
ed with severe disease and risk for disease progres-
sion in patients with rheumatoid arthritis (RA).
 ► The 2019 EULAR management guidelines for RA 
recommend early treatment escalation for patients 
with these poor prognostic factors (PPFs) who have 
inadequate response to first- line therapy.
What does this study add?
 ► Filgotinib efficacy and safety in patients with RA with 
PPFs were consistent with the overall RA phase III 
study population and previous studies.
 ► Treatment with filgotinib 200 mg once daily in 
combination with methotrexate (MTX) resulted in 
higher rates of positive clinical, functional and struc-
tural outcomes compared with MTX alone in this 
population.
How might this impact on clinical practice or 
further developments?
 ► Efficacy of filgotinib 200 mg plus MTX is not im-
paired in patients with PPFs.
 ► Filgotinib may be an alternative treatment option for 
patients with RA who have PPFs, especially those 
not responding to standard treatment such as MTX.
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of remission or low disease activity within 6 months.1 The 
choice of second- line treatment is stratified by the pres-
ence of poor prognostic factors (PPFs) associated with 
rapid disease progression, including elevated acute- phase 
reactant levels; high swollen joint count; seropositivity—
especially with high titres—for rheumatoid factor (RF) 
or anticyclic citrullinated peptide (CCP) antibodies; pres-
ence of early erosions; and persistent moderate or high 
disease activity.1 Treatment escalation to biologic disease- 
modifying antirheumatic drug (bDMARD) or targeted 
synthetic DMARD (tsDMARD) therapy is recommended 
for patients who present with any of these PPFs and do 
not achieve their treatment target; in patients without 
these factors, another conventional synthetic DMARD 
(csDMARD) strategy could be considered after first- line 
treatment failure.1
The EULAR guidelines acknowledge evidence 
supporting this strategy is limited, and the research 
agenda put forward in this EULAR- endorsed docu-
ment includes treatment outcomes in patients with and 
without PPFs.1 Furthermore, although these PPFs histor-
ically predict radiographic progression of joint damage 
in patients treated with csDMARDs or tumour necrosis 
factor (TNF) inhibitors,2–5 data are relatively sparse 
regarding their effect on radiographic outcomes and 
physical function following first- line treatment with non- 
TNF bDMARDs or tsDMARDs such as Janus- associated 
kinase (JAK) inhibitors. Data are needed on efficacy of 
bDMARDs or tsDMARDs versus csDMARDs for clinical 
and radiographic outcomes in patients with PPFs.
Filgotinib is a once- daily oral, JAK1- preferential inhib-
itor with demonstrated efficacy and a favourable safety 
profile in adults with moderately to severely active RA.6–11 
The phase III, randomised, active- controlled FINCH 3 
trial (NCT02886728), which evaluated filgotinib effi-
cacy and safety in MTX- naive patients with RA, included 
patients with at least one marker or risk factor for rapidly 
progressive disease.11 Here, we assessed filgotinib efficacy 
and safety in the subgroup of patients with all of four 
PPFs present at baseline.
METHODS
Study design, patients and treatments
The FINCH 3 trial was previously described in detail.11 
Briefly, MTX- naive adult patients with moderately to 
severely active RA were randomised 2:1:1:2 to receive oral 
filgotinib 200 mg once daily plus oral MTX ≤20 mg once 
weekly, oral filgotinib 100 mg plus oral MTX, oral filgo-
tinib 200 mg monotherapy or oral MTX monotherapy 
for up to 52 weeks. Patients enrolled in FINCH 3 were 
required to have ≥1 of the following at screening: sero-
positivity for RF or anti- CCP antibodies (determined 
by the central laboratory); serum high- sensitivity C 
reactive protein (hsCRP) ≥4 mg/L; or ≥1 documented 
joint erosion on radiographs of the hands, wrists or 
feet by central reading. For this post hoc analysis, PPFs 
were defined as seropositivity for RF and/or anti- CCP 
antibodies, serum hsCRP ≥4 mg/L, disease activity score 
in 28 joints with C reactive protein (DAS28(CRP)) >5.1 
(ie, high disease activity) and erosion score >0 at base-
line. These parameters were chosen because they are 
recognised PPFs that are applicable in the FINCH 3 study 
population and compatible with the eligibility criteria.
The study protocol was reviewed and approved by all 
local institutional review boards or ethics committees. 
The study was carried out in accordance with the Decla-
ration of Helsinki and the International Council for 
Harmonisation Good Clinical Practice guidelines. All 
patients provided consent to participate.
Assessments and endpoints
The schedule of assessments was previously reported.11 
Briefly, clinical assessments and patient questionnaires 
were administered and adverse events (AEs) were 
recorded at each study visit. Radiographs of bilateral 
hands, wrists and feet obtained at screening, week 24 and 
week 52/end- of- treatment were scored by two central 
readers blinded to order of films, patient characteristics 
and treatment group; in case of disagreement, a third 
reader adjudicated the scores.
Efficacy outcomes evaluated in this post hoc analysis 
included proportion of patients with 20% improve-
ment from baseline in American College of Rheuma-
tology core criteria (ACR20) at week 24, the primary 
outcome for FINCH 3; ACR20/50/70 response rates 
through week 52 were also assessed.12 Additional clinical 
outcomes were change from baseline Clinical Disease 
Activity Index (CDAI) and Simplified Disease Activity 
Index (SDAI) and proportions of patients who achieved 
DAS28(CRP) <2.6 or ≤3.2; disease remission was defined 
as CDAI ≤2.8, SDAI≤3.3 or Boolean remission, and low 
disease activity was defined as CDAI ≤10 or SDAI≤11 
through week 52.13–15 Patient- reported outcomes 
included change from baseline in Health Assessment 
Questionnaire- Disability Index (HAQ- DI) and change 
from baseline in the Subject’s Pain Assessment.16 17 Radio-
graphic progression was assessed as change from baseline 
in van der Heijde modified total Sharp score (mTSS) at 
week 24 and week 52 and proportion of patients with 
change from baseline mTSS ≤0 at weeks 24 and 52 
(details are present in online supplemental methods).18
Safety was evaluated from AEs, coded according to the 
Medical Dictionary for Regulatory Activities V.22.0, and 
graded using Common Terminology Criteria for Adverse 
Events V.4.03; and laboratory safety assessments. Poten-
tial major adverse cardiac events and venous thrombotic 
events were adjudicated centrally, and positively adjudi-
cated events are reported.
Statistical analysis
Efficacy and safety analyses were performed in all 
randomised patients who received ≥1 dose of study medi-
cation as previously described.11 No formal hypothesis 
testing was performed to compare patients with PPFs 
versus the overall population, and all such comparisons 
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are descriptive. Exploratory post hoc analyses were 
performed in patients with all four PPFs comparing effi-
cacy across treatments within this risk factor population. 
Analyses of binary endpoints were performed using Fish-
er’s exact test for comparisons between each filgotinib 
dose versus MTX monotherapy; patients with missing data 
were imputed as non- responders. The number of patients 
needed to be treated with each dose of filgotinib versus 
MTX monotherapy for one additional patient to achieve 
binary endpoints (‘number needed to treat;’ NNT) were 
determined based on rate differences in each endpoint 
between patients receiving each filgotinib dose and MTX 
monotherapy. The 95% CI of the rate difference was 
based on a normal approximation method with a conti-
nuity correction; when the 95% CI of the rate difference 
spanned 0, the 95% CI of the NNT was not presented. 
The change from baseline in continuous endpoints was 
evaluated using a mixed model for repeated measures 
with treatment, visit, treatment by visit interaction and 
baseline value included as fixed effects and patient as a 
random effect; missing data were not imputed. Modifi-
cations for the analysis of mTSS change from baseline at 
week 52 are detailed in online supplemental methods. 
Selected efficacy and safety analyses were repeated in 
subgroups of patients with four PPFs with and without 
baseline glucocorticoid use. Efficacy was also explored in 
subgroups of patients with disease duration <6 months 
versus ≥6 months; patients with only three, two or one 
PPFs; and patients with specific combinations of PPFs. 
Post hoc analyses were not adjusted for multiple compar-
isons, and nominal p values are presented.
RESULTS
Patients
Of all 1249 patients who were randomised and received 
study drug, 510 (40.8%) had all four PPFs at baseline; 
397 (77.8%) patients with all four PPFs completed study 
treatment through week 52, compared with 78.1% of the 
overall population (online supplemental figure 1). As 
expected, and partly by definition, patients with all four 
PPFs had greater structural damage (mean mTSS: 17.9 
vs 13.3), poorer functional status (HAQ- DI: 1.76 vs 1.56), 
higher disease activity (CDAI: 44.3 vs 39.8; SDAI: 47.1 vs 
41.5; DAS28(CRP): 6.3 vs 5.7; hsCRP: 27.9 vs 17.5 mg/L) 
and higher rate of seropositivity for RF (90.6% vs 67.9%), 
anti- CCP antibodies (92.4% vs 68.5%) or both (82.9% vs 
59.6%) compared with the overall population (table 1). 
In total, 44.9% of patients with four PPFs had concur-
rent oral glucocorticoid therapy at baseline, compared 
with 39.6% in the overall population (table 1). Baseline 
characteristics were generally similar between patients 
with four PPFs with versus without baseline glucocorti-
coid use except for longer mean duration of RA (3.3 vs 
1.7 years), greater frequency of csDMARD use (21.4% vs 
15.3%) and concurrent antimalarial use (13.5% vs 6.4%) 
and higher mean baseline mTSS score (21.8 vs 14.7).
Efficacy
American College of Rheumatology responses
Compared with the overall study population, patients 
with four PPFs had similar or numerically higher ACR 
response rates, although no formal analysis was performed 
(figure 1A–C). Among patients with four PPFs, treatment 
with filgotinib 200 mg plus MTX versus MTX mono-
therapy was associated with higher rates (95% CI) of 
ACR20, ACR50 and ACR70 responses at week 24 (85.5% 
(79.9% to 91.0%)/70.3% (63.2% to 77.5%)/54.1% 
(46.3% to 61.8%) vs 74.7% (67.8% to 81.6%)/48.2% 
(40.3% to 56.1%)/28.3% (21.2% to 35.5%)), as well as 
weeks 12 and 52 (nominal p<0.05 for all comparisons; 
figure 1A–C). The ACR20/50/70 response rates were 
not consistently different in patients receiving filgotinib 
100 mg plus MTX or filgotinib 200 mg monotherapy rela-
tive to MTX monotherapy (figure 1A–C).
Disease activity and remission measures
In both patients with four PPFs and the overall popula-
tion, achievement of low disease activity at weeks 24 and 
52 was more frequent (nominal p<0.05 for all measures) 
among patients treated with any filgotinib regimen rela-
tive to MTX monotherapy (figure 2A). Compared with 
the overall population, patients with four PPFs achieved 
DAS28(CRP) <2.6 and all remission measures at similar 
or numerically higher rates following treatment with 
filgotinib 200 mg with or without MTX, but at numerically 
lower rates following treatment with filgotinib 100 mg plus 
MTX or MTX monotherapy, at week 24 (figure 2B,C). 
Only patients receiving filgotinib 200 mg plus MTX 
maintained comparable rates of DAS28(CRP) <2.6 and 
remission relative to the overall population at week 52 
(figure 2B,C).
The proportion (95% CI) of patients with four PPFs 
who achieved DAS28(CRP) <2.6, CDAI≤2.8, SDAI≤3.3 or 
Boolean remission was higher following 24 weeks of treat-
ment with filgotinib 200 mg with MTX (53.5% (45.7% 
to 61.2%), 27.3% (20.4% to 34.3%), 29.7% (22.5% to 
36.8%) or 25.0% (18.2% to 31.8%), respectively) or filgo-
tinib 200 mg monotherapy (40.2% (29.4% to 51.1%), 
19.5% (10.6% to 28.4%), 19.5% (10.6% to 28.4%) or 
16.1% (7.8% to 24.4%), respectively) versus MTX mono-
therapy (21.1% (14.6% to 27.6%), 8.4% (3.9% to 13.0%), 
7.2% (3.0% to 11.5%) or 7.2% (3.0% to 11.5%), respec-
tively; nominal p<0.05 for all measures). However, only 
the response rate for SDAI≤3.3 was greater in patients 
receiving filgotinib 100 mg plus MTX versus MTX 
monotherapy (16.5% (8.0% to 24.9%) vs 7.2% (3.0% to 
11.5%); figure 2B,C). In contrast, in the overall FINCH 
3 population, the proportions of patients achieving 
DAS28(CRP) <2.6 and remission at week 24 were higher 
following treatment with any filgotinib regimen rela-
tive to MTX monotherapy (figure 2B,C). At week 52, 
DAS28(CRP) <2.6 and remission rates remained higher 
in patients with four PPFs receiving filgotinib 200 mg 
plus MTX versus MTX monotherapy (figure 2B,C). No 
differences were observed in the response rates for the 
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majority of these measures following treatment with filgo-
tinib 100 mg plus MTX or filgotinib 200 mg monotherapy 
versus MTX monotherapy at week 52 (figure 2B,C).
Improvements from baseline in CDAI (figure 3A) and 
SDAI (figure 3B) were present at week 12 for patients 
with four PPFs receiving any filgotinib treatment regimen 
relative to MTX monotherapy and persisted through 
week 52 (nominal p<0.05 at weeks 12, 24, and 52). 
Although no formal analysis was performed, the filgo-
tinib treatment effect appeared comparable or better in 
patients with four PPFs relative to the overall population 
(figure 3A,B).
To further explore the clinical benefit of filgotinib treat-
ment in patients with four PPFs, the NNT for one addi-
tional patient to achieve treatment endpoints for each 
dose of filgotinib versus MTX monotherapy was calcu-
lated for ACR20/50/70 response, low disease activity, 
and remission (figure 4). Among patients receiving filgo-
tinib 200 mg plus MTX, the NNT was lower for patients 
with four PPFs relative to the overall population for all 
Table 1 Demographics and baseline clinical characteristics of patients with all four poor prognostic factors and the overall 
study population
Patients with four poor prognostic factors Overall
FIL 200 mg + MTX
n=172










Age, years 51±12.9 53±12.9 50±12.8 53±12.9 52±12.9 53±13.6
Female, n (%) 133 (77.3) 65 (76.5) 67 (77.0) 128 (77.1) 393 (77.1) 961 (76.9)
RA duration, years 1.8±3.40 2.8±5.50 2.4±6.27 2.7±6.16 2.4±5.29 2.2±4.97
  Median (min, max) 0.4 (0, 26.8) 0.6 (0.1, 31.7) 0.3 (0, 47.2) 0.6 (0, 52.3) 0.5 (0, 52.3) 0.4 (0, 52.3)
  ≤6 months, n (%) 89 (51.7) 41 (48.2) 50 (57.5) 78 (47.0) 258 (50.6) 686 (54.9)
  6 months–1 year, n (%) 22 (12.8) 13 (15.3) 7 (8.0) 24 (14.5) 66 (12.9) 140 (11.2)
  ≥1 year, n (%) 61 (35.5) 31 (36.5) 30 (34.5) 64 (38.6) 186 (36.5) 423 (33.9)
Prior non- MTX csDMARD use, 
n (%)
25 (14.5) 17 (20.0) 15 (17.2) 35 (21.1) 92 (18.0) 222 (17.8)
Prior exposure to MTX, n (%) 12 (7.0) 7 (8.2) 9 (10.3) 10 (6.0) 38 (7.5) 82 (6.6)
Concurrent oral glucocorticoid 
use, n (%)
61 (35.5) 45 (52.9) 45 (51.7) 78 (47.0) 229 (44.9) 494 (39.6)
  Glucocorticoid dose, mg/day 6.9±2.44 7.2±2.59 6.5±2.09 6.3±2.31 6.7±2.37 6.6±2.43
Concurrent antimalarial use, 
n (%)
12 (7.0) 12 (14.1) 6 (6.9) 19 (11.4) 49 (9.6) 118 (9.4)
Seropositivity
  RF, n (%) 162 (94.2) 75 (88.2) 77 (88.5) 148 (89.2) 462 (90.6) 848 (67.9)
  Anti- CCP, n (%) 162 (94.2) 76 (89.4) 76 (87.4) 157 (94.6) 471 (92.4) 855 (68.5)
  RF and anti- CCP, n (%) 152 (88.4) 66 (77.6) 66 (75.9) 139 (83.7) 423 (82.9) 744 (59.6)
  hsCRP, mg/L 31.6±31.3 28.0±28.5 23.3±24.6 26.3±27.1 27.9±28.5 17.5±25.0
  mTSS erosions >0, n (%) 172 (100) 85 (100) 87 (100) 166 (100) 510 (100) 1173 (93.9)
  SJC66 20±11.4 19±10.8 19±10.8 18±10.1 19±10.8 16.0±9.6
  TJC68 30±14.3 29±13.1 28±13.6 28±14.3 29±14.0 26.0±14.0
  Pain (VAS) 73±17.0 73±19.0 72±16.4 73±17.0 73±17.2 65±21.3
  HAQ- DI 1.73±0.59 1.79±0.63 1.72±0.69 1.81±0.55 1.76±0.60 1.56±0.634
  DAS28(CRP) 6.4±0.73 6.3±0.72 6.2±0.67 6.3±0.72 6.3±0.72 5.7±0.99
  CDAI 44.8±12.0 45.1±11.1 42.7±11.9 44.2±11.1 44.3±11.5 39.8±12.6
  SDAI 47.9±12.3 47.9±11.8 45.0±11.7 46.8±11.8 47.1±11.9 41.5±13.4
  mTSS units* 13.2±23.1 18.1±35.9 24.2±44.3 19.3±37.2 17.9±34.5 13.3±26.7
Data are shown as mean±SD unless otherwise noted.
*Campaign A.
CCP, cyclic citrullinated peptide; CDAI, Clinical Disease Activity Index; csDMARD, conventional synthetic disease- modifying antirheumatic 
drug; DAS28(CRP), disease activity score in 28 joints with C reactive protein; FIL, filgotinib; HAQ- DI, Health Assessment Questionnaire- 
Disability Index; hsCRP, high- sensitivity C reactive protein; mTSS, van der Heijde modified total Sharp score; MTX, methotrexate; RA, 
rheumatoid arthritis; RF, rheumatic factor; SD, standard deviation 
; SDAI, Simplified Disease Activity Index; SJC, swollen joint count; TJC, tender joint count; VAS, visual analogue scale.
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endpoints (ACR20, 9 vs 10; ACR50, 5 vs 6; ACR70, 4 vs 6; 
DAS28(CRP) ≤3.2, 3 vs 4; CDAI≤10, 4 vs 6; SDAI≤11, 4 vs 
5; DAS28(CRP) <2.6, 3 vs 4; CDAI≤2.8, 5 vs 8; SDAI≤3.3, 
4 vs 6; Boolean remission, 6 vs 9; figure 4A). For CDAI 
and SDAI low disease activity and remission, NNT was 
also lower among patients with four PPFs receiving filgo-
tinib 200 mg monotherapy compared with the overall 
population (DAS28(CRP) ≤3.2, 5 vs 7; CDAI≤10, 7 vs 12; 
SDAI≤11, 6 vs 9; DAS28(CRP) <2.6, 5 vs 8; CDAI≤2.8, 
9 vs 12; SDAI≤3.3, 8 vs 9; Boolean remission, 11 vs 15; 
figure 4B); no consistent differences in NNT between the 
PPF and overall populations were observed in patients 
receiving filgotinib 100 mg plus MTX (figure 4C).
Physical function
Treatment with any filgotinib regimen versus MTX mono-
therapy was associated with similar or greater improve-
ment from baseline in physical function and patient- 
assessed pain among patients with four PPFs relative to 
the overall population (figure 5A,B). Mean (SD) change 
from baseline HAQ- DI at week 24 among patients with 
four PPF was larger following treatment with filgotinib 
200 mg plus MTX (−1.19 (0.729)), filgotinib 100 mg plus 
MTX (−1.02 (0.691)), or filgotinib 200 mg monotherapy 
(−1.00 (0.630)) compared with MTX monotherapy 
(−0.86 (0.634); nominal p<0.05; figure 5A). This treat-


































































































































































































Patients with 4 poor prognostic factors
***
FIL 200 mg + MTX (n = 172 PPF/416 overall)
FIL 100 mg + MTX (n = 85 PPF/207 overall)
FIL 200 mg (n = 87 PPF/210 overall)
MTX (n = 166 PPF/416 overall)
Figure 1 Proportions of patients achieving ACR20/50/70 at (A) week 12, (B) week 24 and (C) week 52. Error bars represent 
the 95% CI. #p<0.05, ###p<0.001 versus MTX; *nominal p<0.05, **nominal p<0.01, ***nominal p<0.001 versus MTX. ACR20/50/70, 
20%/50%/70% improvement from baseline in American College of Rheumatology core criteria; FIL, filgotinib; MTX, 
methotrexate; PPF, patients with four poor prognostic factors.
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treated with filgotinib 200 mg with or without MTX, but 
not filgotinib 100 mg plus MTX, relative to MTX mono-
therapy (figure 5A). Similarly, patient- assessed pain was 
further decreased from baseline at weeks 24 and 52 in 
patients treated with filgotinib 200 mg plus MTX (mean 
(SD), −52 (26.3) at week 24) or filgotinib 200 mg mono-
therapy (mean (SD), −44 (24.6) at week 24), but not in 
patients receiving filgotinib 100 mg plus MTX (mean 
(SD), −42 (26.5) at week 24), relative to MTX mono-
therapy (mean (SD), −39 (27.1) at week 24 (figure 5B).
Radiographic progression
Radiographic progression was numerically greater in 
patients with all four PPFs compared with the overall 
population (figure 6A,B). Among patients with four 
PPFs, radiographic progression at week 24 based on 
least- squares mean (SE) change from baseline mTSS 
was decreased in patients treated with filgotinib 200 mg 
plus MTX (0.26 (0.240)) or filgotinib 200 mg mono-
therapy (−0.18 (0.354)), but not filgotinib 100 mg plus 












































































































































































































































































FIL 200 mg + MTX (n = 172 PPF/416 overall)
FIL 100 mg + MTX (n = 85 PPF/207 overall)
FIL 200 mg (n = 87 PPF/210 overall)
MTX (n = 166 PPF/416 overall)
FIL 200 mg + MTX (n = 172 PPF/416 overall)
FIL 100 mg + MTX (n = 85 PPF/207 overall)
FIL 200 mg (n = 87 PPF/210 overall)
MTX (n = 166 PPF/416 overall)
FIL 200 mg + MTX (n = 172 PPF/416 overall)
FIL 100 mg + MTX (n = 85 PPF/207 overall)
FIL 200 mg (n = 87 PPF/210 overall)
MTX (n = 166 PPF/416 overall)
Figure 2 (A) Proportions of patients with four PPFs (left) and the overall population (right) achieving low disease activity at 
weeks 24 and 52. (B) Proportions of patients with four PPFs (left) and all FINCH 3 patients (right) achieving DAS28(CRP) <2.6 
over time through week 52. (C) Proportions of patients achieving remission defined by CDAI≤2.8, SDAI≤3.3 or Boolean 
remission criteria at weeks 24 (left) and 52 (right). Error bars represent the 95% CI. ###p<0.001, *nominal p<0.05, **nominal 
p<0.01, ***nominal p<0.001 versus MTX. CDAI, Clinical Disease Activity Index; DAS28(CRP), Disease Activity Score in 28 joints 
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Figure 3 Treatment effect of filgotinib regimens versus MTX monotherapy on change from baseline in (A) CDAI and (B) SDAI 
at weeks 12, 24 and 52. CDAI, Clinical Disease Activity Index; FIL, filgotinib; LSM, least squares mean; MTX, methotrexate; 
PPF, patients with four poor prognostic factors; SDAI, Simplified Disease Activity Index.
copyright.
 on A












pen: first published as 10.1136/rm





8 Aletaha D, et al. RMD Open 2021;7:e001621. doi:10.1136/rmdopen-2021-001621
RMD Open
(0.244); figure 6A). At week 52, patients had less radi-
ographic progression following treatment with all filgo-
tinib regimens relative to MTX monotherapy (figure 6B). 
Proportions of patients with no radiographic progression 
(defined as mTSS ≤0) at week 24 are shown in online 
supplemental table 1 and odds ratios for no radiographic 
progression at week 52 following treatment with filgo-
tinib versus MTX monotherapy in online supplemental 
table 2.
Subgroup analyses
Efficacy in subgroups of patients with four PPFs with 
and without baseline glucocorticoid use was similar to 
results in all patients with four PPFs, as shown for ACR20 
response and SDAI remission rate at week 24 in online 
supplemental figure 2. Disease duration ≥6 months 
versus <6 months had no apparent effect on ACR20 
response rate (online supplemental figure 2A); however, 
while rates of remission by SDAI at week 24 were also 
similar across filgotinib treatment arms among patients 
with early disease (<6 months), patients with established 
disease (≥6 months) had higher SDAI remission rates 
following treatment with filgotinib 200 mg (regardless 
of MTX use) versus filgotinib 100 mg plus MTX or MTX 
monotherapy (online supplemental figure 2B).
In exploratory analyses, treatment with filgotinib, espe-
cially in combination with MTX, also resulted in higher 
SDAI remission rates (nominal p<0.05) compared with 
MTX monotherapy in patients with four PPFs. Patients 
treated with filgotinib plus MTX versus MTX mono-
therapy had higher SDAI remission rates at week 24 
across all combinations of three or two PPFs examined 
(nominal p<0.05), with numerical trends for higher rates 
of SDAI remission at week 24 in patients receiving filgo-
tinib 200 mg monotherapy versus MTX monotherapy, 
as well (online supplemental figure 3). Treatment with 
filgotinib 200 mg plus MTX was generally more effective 
versus filgotinib 100 mg plus MTX or filgotinib 200 mg 
monotherapy only in patients with four PPFs and with 
the examined combinations of PPFs—particularly 
among patients with erosions, seropositivity and CRP ≥4; 
erosions, DAS28(CRP) >5.1, and CRP ≥4; or erosions and 
CRP ≥4—but not among patients with only three or two 
PPFs overall (online supplemental figure 3).
Safety
Treatment- emergent AEs (TEAEs) among patients with 
four PPFs, including frequencies of all TEAEs, TEAEs of 
severity grade ≥3, serious TEAEs and TEAEs leading to 
temporary study treatment interruption or premature 
discontinuation, were generally similar to those in the 
overall population and comparable among treatment 
arms (table 2).
The TEAEs of special interest were generally similar 
between patients with four PPFs and the overall popu-
lation and among treatment arms within each popu-
lation, with some possible exceptions (table 2). The 
frequency of infectious TEAEs was higher among 
patients with PPFs treated with filgotinib 100 mg plus 
MTX or filgotinib 200 mg monotherapy relative to both 
similarly treated patients in the overall population and 
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Figure 4 Number of patients needed to treat with (A) filgotinib 200 mg plus MTX, (B) filgotinib 100 mg plus MTX or (C) filgotinib 
200 mg monotherapy versus MTX monotherapy for one additional patient to achieve clinical endpoints. 95% CI of NNT not 
shown where the 95% CI of the rate difference between FIL and MTX spanned 0. ACR20/50/70, 20%/50%/70% improvement 
from baseline in American College of Rheumatology core criteria; CDAI, Clinical Disease Activity Index; DAS28(CRP), disease 
activity score in 28 joints with C reactive protein; FIL, filgotinib; MTX, methotrexate; NNT, number needed to treat; PPF, patients 
with four poor prognostic factors; SDAI, Simplified Disease Activity Index.
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infections occurred with higher frequency in patients 
with four PPFs receiving filgotinib 200 mg plus MTX 
(2.3%; n=4) or filgotinib 100 mg plus MTX (3.5%; n=3) 
relative to patients in the overall population receiving 
the same treatment or patients with PPFs treated with 
filgotinib 200 mg monotherapy (1.1%; n=1) or MTX 
monotherapy (1.8%; n=3). Other AEs of special interest 
in patients with PPFs occurred in ≤3 patients receiving 
any treatment regimen (table 2). Herpes zoster infec-
tion occurred at low frequency in all treatment arms: 
1.2%, 2.4%, 3.4% and 0.6% of patients receiving filgo-
tinib 200 mg plus MTX, filgotinib 100 mg plus MTX, 
filgotinib 200 mg monotherapy and MTX monotherapy, 
respectively.
Figure 5 Treatment difference versus MTX monotherapy in change from baseline in (A) HAQ- DI and (B) patient pain 
assessment at weeks 24 and 52. aNot adjusted for multiplicity except where indicated. bAdjusted for multiplicity. FIL, filgotinib; 
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The overall AE rates were similar in subgroups of 
patients with four PPFs with and without baseline gluco-
corticoid use within all treatment arms including MTX 
monotherapy. Glucocorticoid use was associated with 
higher frequency of infection within the filgotinib 100 mg 
plus MTX and filgotinib 200 mg monotherapy treatment 
arms compared with patients in the same treatment arm 
not receiving glucocorticoids. The frequency of serious 
infection was also higher in patients with versus without 
glucocorticoid use within the filgotinib 100 mg plus MTX 
(3 (6.7%) with vs 0 without glucocorticoid use) and 
MTX monotherapy (2 (2.6%) with vs 1 (1.1%) without 
glucocorticoid use) treatment arms. Other AEs of special 
interest occurred in fewer than three patients in each 
glucocorticoid use subgroup.
DISCUSSION
This post hoc analysis of FINCH 3 comprehensively 
assessed all relevant outcome domains of RA, including 
achievement of clinical response, clinical target states, 
functional improvement and inhibition of structural 
progression in patients with multiple PPFs at baseline. 
Such patients are generally expected to experience poor 
outcomes compared with patients without these risk 
factors, hence their designation as PPFs.2–5 In this study, 
treatment with filgotinib 200 mg plus MTX resulted in 
comparable efficacy relative to the overall population 
across clinical, functional and structural measures. The 
filgotinib 200 mg plus MTX regimen in particular had 
an incremental benefit versus MTX monotherapy in the 
multiple PPFs population; an added benefit of filgotinib 
100 mg plus MTX and filgotinib 200 mg monotherapy 
versus MTX monotherapy was observed but inconsistent 
in this high- risk population. Patients with established 
RA (disease duration ≥6 months) may also benefit more 
from treatment with filgotinib 200 mg in combination 
with MTX relative to filgotinib 100 mg plus MTX, filgo-
tinib 200 mg monotherapy or MTX alone.
Interpretation of subgroup analyses of patients 
with  four PPFs was limited by small patient numbers 
and imbalances among treatment groups, as well as by 
better baseline status and/or slower progression in these 
patients relative to those with all four PPFs. Within these 
limitations, patients with all four PPFs were more likely to 
Figure 6 Change in mTSS from baseline at (A) week 24 and (B) week 52. *Nominal p<0.05, **nominal p<0.01. FIL, filgotinib; 
LS, least squares; mTSS, van der Heijde modified total Sharp score; MTX, methotrexate.
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benefit from treatment with filgotinib (all doses) versus 
MTX monotherapy relative to patients with  four PPFs. 
However, efficacy of filgotinib in combination with MTX 
versus MTX monotherapy was maintained in patients 
with only three or only two PPFs. Treatment with filgo-
tinib 200 mg plus MTX appeared more effective versus 
filgotinib 100 mg plus MTX or filgotinib 200 mg mono-
therapy in patients with examined combinations of PPFs 
and particularly within subgroups of patients with CRP 
≥4, possibly because filgotinib reduces CRP in a dose- 
dependent manner. It is possible that elevated serum CRP 
levels indicate greater inflammation and thus require a 
higher dose of filgotinib and/or combination therapy to 
suppress JAK- mediated inflammatory pathways. However, 
interpretation of this observation is limited by the rela-
tively small numbers of patients with all four PPFs.
AEs in patients with four PPFs were generally compa-
rable both to results in the overall population and 
between patients receiving treatment with all filgotinib 
regimens versus MTX monotherapy. The exceptions 
were infections, serious infections and herpes zoster 
infections, which were more frequent in patients with 
four PPFs receiving some filgotinib doses compared 
with either patients in the overall population receiving 
the same treatment or patients with PPFs receiving 
other treatments. The numbers of cases were too small 
to support any conclusions about safety in patients with 
PPFs relative to the overall population. In general, the 
safety profile of filgotinib relative to MTX in MTX- naive 
patients in FINCH 3 was maintained in this population 
and consistent with the integrated safety analysis.19 This 
is reassuring, as more AEs might be expected in this high 
disease activity subgroup relative to the overall study 
population.
This analysis was limited by its post hoc nature and 
the primary study design. The study was not powered for 
subgroup comparisons, and numbers of patients with four 
PPFs in each treatment arm were small. Relative impor-
tance of each of the four PPFs to patient outcomes was not 
assessed. Regression to the mean may have contributed to 
improvement in clinical outcomes due to the high base-
line disease activity in patients with four PPFs, although 
no evidence of this was seen for radiographic outcomes. 
The EULAR guidelines note that bDMARDs and 
tsDMARDs are not recommended as first- line treatments 
because these do not clearly demonstrate superiority to 
MTX plus glucocorticoids.1 This could not be examined 
in the present study, which was not designed to compare 
treatment regimens with and without glucocorticoids. 
Of note, 45% of patients with four PPFs were receiving 
Table 2 Treatment- emergent AEs in patients with four PPFs and the overall population
FIL 200 mg + MTX FIL 100 mg + MTX FIL 200 mg MTX
PPF-4 Overall PPF-4 Overall PPF-4 Overall PPF-4 Overall
n 172 416 85 207 87 210 166 416
All AEs 125 (72.7) 318 (76.4) 68 (80.0) 164 (79.2) 57 (65.5) 143 (68.1) 118 (71.1) 305 (73.3)
Grade ≥3 AEs 17 (9.9) 50 (12.0) 15 (17.6) 26 (12.6) 6 (6.9) 18 (8.6) 15 (9.0) 40 (9.6)
Serious AEs 8 (4.7) 26 (6.3) 9 (10.6) 13 (6.3) 7 (8.0) 17 (8.1) 15 (9.0) 28 (6.7)
AEs leading to temporary 
interruption of study drug
40 (23.3) 102 (24.5) 19 (22.4) 46 (22.2) 14 (16.1) 28 (13.3) 31 (18.7) 97 (23.3)
AEs leading to premature 
discontinuation of study drug
12 (7.0) 28 (6.7) 8 (9.4) 13 (6.3) 1 (1.1) 5 (2.4) 13 (7.8) 25 (6.0)
Death* 0 3 (0.7) 1 (1.2) 1 (0.5) 0 0 0 0
Infections 56 (32.6) 148 (35.6) 35 (41.2) 76 (36.7) 37 (42.5) 75 (35.7) 55 (33.1) 157 (37.7)
Serious infections 4 (2.3) 5 (1.2) 3 (3.5) 3 (1.4) 1 (1.1) 5 (2.4) 3 (1.8) 8 (1.9)
Opportunistic infections 1 (0.6) 1 (0.2) 0 0 0 0 1 (0.6) 2 (0.5)
Herpes zoster 2 (1.2) 6 (1.4) 2 (2.4) 3 (1.4) 3 (3.4) 4 (1.9) 1 (0.6) 4 (1.0)
Active tuberculosis 0 0 0 0 0 0 0 0
MACE 0 4 (1.0) 1 (1.2) 1 (0.5) 1 (1.1) 2 (1.0) 1 (0.6) 2 (0.5)
VTE 0 0 0 0 0 0 1 (0.6) 2 (0.5)
Malignancy (excluding NMSC) 0 1 (0.2) 0 0 0 0 0 4 (1.0)
NMSC 1 (0.6) 2 (0.5) 0 0 0 0 1 (0.6) 1 (0.2)
Gastrointestinal perforation 1 (0.6) 1 (0.2) 0 0 0 0 0 0
Data are presented as n (%).
Only positively adjudicated MACE and VTE are reported.
*The causes of death included lupus myocarditis (possible overlapping systemic autoimmune disease), intracranial aneurysm, interstitial lung 
disease and sudden cardiovascular death, which occurred 68 days after treatment discontinuation.
AE, adverse event; FIL, filgotinib; MACE, major adverse cardiovascular event; MTX, methotrexate; NMSC, non- melanoma skin cancer; PPF-
4, patients with all four poor prognostic factors; VTE, venous thromboembolism.
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glucocorticoids, all dosed at ≤10 mg, at baseline (table 1). 
Glucocorticoid use did not appear to affect efficacy or 
safety of filgotinib in this population with the exception 
of greater numbers of infections in patients with versus 
without glucocorticoid use. However, interpretation is 
limited by the small numbers of patients and events in 
these post hoc ‘subgroup of subgroup’ analyses. Among 
patients with four PPFs, glucocorticoid use at baseline 
was associated with longer disease duration and more 
radiographic damage. These findings indirectly confirm 
current EULAR recommendations for glucocorticoid use 
in patients with RA as short- term ‘bridging’ therapy in 
conjunction with prompt initiation of DMARDs but not as 
monotherapy.1 EULAR also requested data on outcomes 
in patients both with and without PPFs,1 but the FINCH 
3 trial population did not allow comparison of outcomes 
relative to patients without any PPFs because all patients 
had at least one PPFs per study inclusion criteria.
The results of the present study confirm that MTX- 
naive patients with RA with PPFs are at risk for treat-
ment failure and radiographic progression following 
MTX monotherapy. These patients may thus warrant 
additional consideration of treatment escalation at the 
3- month checkpoint. Treatment with filgotinib 200 mg 
plus MTX provided rapid and clinically meaningful 
improvement in disease control, including higher rates 
of remission, improved physical function and less radio-
graphic progression, compared with MTX alone in MTX- 
naive patients with four PPFs. Treatment with filgotinib 
100 mg plus MTX or filgotinib 200 mg monotherapy 
also showed some incremental benefit over MTX mono-
therapy in this population. The risk/benefit balance for 
filgotinib 200 mg plus MTX treatment appears reason-
able in patients with RA with multiple PPFs, and filgo-
tinib could be part of the treatment strategy for these 
patients. Given the efficacy of filgotinib 200 mg plus MTX 
in particular versus MTX monotherapy in this popula-
tion, addition of filgotinib may be a reasonable option 
for patients with PPFs who have unsatisfactory response 
to MTX plus glucocorticoids or who relapse on glucocor-
ticoid tapering.
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